RxDoctor Payments DataLook up a doctor →

Daniel Chueh, MD

Psychiatry · Orange, CANPI 1174589642

Payments from drug & device makers

$17,895,376in general payments, 2019–2025

Across 2,048 payments — averaging $8737.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4.9M
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2.9M
  • AbbVie$2.3M
  • Sage Therapeutics, LLC$1.6M
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$1.5M
  • Hoffmann-la Roche Limited$873K
  • plus $3.8M from 36 others
$4,201in research payments, 2019–2025

Across 35 payments — averaging $120.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$3K
  • Teva Pharmaceuticals USA, Inc.$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.232$4,900,349
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)483$2,861,719
AbbVie(2 entities)259$2,298,927
Sage Therapeutics, LLC64$1,608,110
Otsuka Pharmaceutical Development & Commercialization, Inc.24$1,547,641
Hoffmann-la Roche Limited18$873,249
Vanda Pharmaceuticals Inc.42$763,163
Boehringer Ingelheim49$688,068
Boehringer Ingelheim International GmbH266$568,917
Supernus Pharmaceuticals, Inc.61$518,764
Acadia Pharmaceuticals Inc33$346,688
E.r. Squibb & Sons, L.L.C.24$211,882
Bioxcel Therapeutics, Inc.7$152,238
Janssen Research & Development, LLC27$114,078
Alkermes, Inc.84$85,389
Biohaven Pharmaceutical Holding Company Ltd.1$73,771
Roche TCRC, Inc.5$62,073
Avanir Pharmaceuticals, Inc.23$54,764
Takeda Pharmaceuticals U.S.A., Inc.28$38,249
Otsuka America Pharmaceutical, Inc.80$34,071
H. Lundbeck A S5$33,037
Sunovion Pharmaceuticals Inc.81$24,310
Jazz Pharmaceuticals Inc.3$16,675
Mallinckrodt LLC2$8,942
Pfizer12$5,192
Boehringer Ingelheim RCV GmbH & Co KG36$2,669
Johnson & Johnson44$1,065
Neurocrine Biosciences, Inc.16$432
Axsome Therapeutics, Inc.5$219
Lundbeck LLC8$184
Indivior Inc.9$161
Eisai Inc.2$71
Novo Nordisk3$66
Ironshore Pharmaceuticals Inc.2$54
Lilly USA, LLC2$43
Noven Therapeutics, LLC2$37
Vertical Pharmaceuticals, LLC1$21
OWP Pharmaceuticals, Inc.1$21
Sun Pharmaceutical Industries Inc.1$20
CMP Pharma, Inc.1$17
Almatica Pharma LLC1$17
Tris Pharma Inc1$14

How this compares

$17,895,376 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Medicare billing

Part B allowed, 2024
$345,053
Medicare patients
1,069
Services billed
3,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Orange

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →